DOW — Dow Inc.

The market mood as of 2026-09-13 is clearly negative despite a headline beat. Q2 2026 (reported 2026-07-23) delivered revenue of $12.09B (+20% y/y) and adjusted EPS of $1.44 vs $1.25 consensus, yet the stock fell 1.1% on the print because volumes were -1% overall and -4% in Packaging & Specialty Plastics, and management guided cautiously for H2. KeyBanc's 2026-09-11 initiation at Sector Weight with a $26 target validated the bear case on structurally weak polyethylene pricing. Price action confirms it: -5.04% over 1 month, -14.24% over 3 months, -20.73% over 6 months as of 2026-09-13, with the shares below the 20-, 50- and 200-day averages, and sell-side consensus stuck at Hold with a $35.67 average target (range $26-$45).

Revenue flatlined for three years - $10.62B (Q4 2023), $10.92B (Q2 2024), $9.46B (Q4 2025) - then printed $12.09B in Q2 2026 (+19.7% y/y). Margins describe a classic trough: gross margin peaked at 12.5% in Q1 2024, compressed to 5.4% in Q2 2025 and 5.8% in Q4 2025, then rebounded to 6.5% (Q1 2026) and 17.9% (Q2 2026); operating income went from +$704M (Q1 2024) to -$1,044M (Q4 2025) to +$882M (Q2 2026), and net income from +$516M to -$1,543M to +$721M. Free cash flow was negative in four of the six quarters from Q1 2024 through Q2 2025, then turned positive at $621M (Q1 2026) and $699M (Q2 2026). Two important qualifiers: (1) with total volumes -1% y/y and P&SP -4%, a +20% revenue jump is not organic demand - it is price/mix or consolidation; (2) stockholders' equity jumped from $15.25B (2026-03-31) to $24.42B (2026-06-30) while total liabilities fell $7.46B, a discontinuity the deterministic score flags as possibly a divestiture, spin, or acquisition. Treat Q2 2026 as an inflection quarter, not yet a confirmed trend.

Cheap on assets and sales, moderately cheap on forward earnings - but partly because the denominator is trough-depressed. As of 2026-09-13: P/B 0.843 (below book), P/S 0.508 vs a 5-year average of 0.67 (~24% discount), forward P/E 11.9x on next-FY consensus EPS of $2.449, and a 4.59% dividend yield at the high end of its own history. The 26.8x 5-year average P/E is not a usable benchmark - it is inflated by near-zero trough earnings (TTM P/E is negative at -16.1x, and the 0.12 PEG is meaningless with cyclical/negative EPS). On the deterministic score's own valuation overlay the stock scores 90.2 ('Cheap vs. its own history'). The honest read: you are buying assets and sales at a discount, and forward earnings at a mid-teens discount to the market, in exchange for accepting that the earnings base is unproven.

The tape is not paying for the recovery the sell side models. At $29.03 you pay ~11.9x next-FY EPS of $2.449 and 0.84x book - the market is capitalising a partial recovery but refusing to fund it with multiple expansion, which is why a 20% revenue beat only moved the stock -1.1%. If FY2027 lands at the $2.45 consensus, a 14x multiple is worth ~$34; if volumes stay negative and EPS lands closer to $1.50, you are paying 19x for a cyclical and today's price is fair-to-rich. The Q3 2026 print (late Oct/early Nov 2026) is the swing factor: if the ~$700M 2026 restructuring benefit holds operating margin near Q2's 7.3% through a seasonally softer quarter, the multiple re-rates; if margins fade back toward Q1's -0.3%, the market's scepticism is vindicated.

As of 2026-09-13 the technical picture was weak but not washed out. RSI(14) stood at 40.19 - soft, not oversold - with price 5.3% below the 20-day (~$30.66), 3.65% below the 50-day (~$30.13) and 8.23% below the 200-day (~$31.63): a clean downtrend with all three moving averages overhead. Trailing returns were -1.39% (1wk), -5.04% (1mo), -14.24% (3mo) and -20.73% (6mo). Timing implication: there is no technical trigger to buy here. A reclaim of the 50-day (~$30.13) or an RSI flush below 30 toward the $26-27 zone (near KeyBanc's $26 target) would offer materially better entries than chasing a falling knife mid-range.

• Polyethylene and commodity chemical oversupply: new global capacity, notably in China and the Middle East, is holding PE spreads near cash-cost levels - the core of KeyBanc's 2026-09-11 bearish initiation.
• North American feedstock cost advantage: cheap natural-gas-derived ethane gives Dow a structural edge over naphtha-based European and Asian producers, but that edge is worth far less when global prices are set by oversupply rather than by the marginal producer's cost.
• Energy and feedstock volatility plus Middle East geopolitics (Iran) as a live input-cost and supply-chain risk for petrochemical producers.
• Higher-for-longer rates: Dow is capital-intensive (TTM capex ~$4.2B, including a $2.48B spike in Q4 2025) and pays a 4.6% dividend, so it competes directly with bond yields and its Alberta cracker economics are discount-rate sensitive.
• Weak global industrial and packaging demand, tariffs and trade friction: Q2 2026 volumes were -1% y/y overall and -4% in Packaging & Specialty Plastics, the segment most levered to global trade.

• Q3 2026 earnings, expected late Oct/early Nov 2026: the key question is whether the ~$700M 2026 restructuring run-rate holds operating margin near Q2's 7.3% and whether management gives quantitative 2027 margin visibility.
• Further 'Transform to Outperform' footprint actions - asset closures, divestitures, or an explanation of the Q2 2026 corporate event behind the $9.2B equity increase and $7.5B liability decrease - which would clarify true leverage.
• A polyethylene price/spread inflection or industry capacity rationalisation announcements, which would re-rate the entire commodity chemical complex.
• Capital spending normalisation: TTM capex of ~$4.2B, bloated by a single $2.48B Q4 2025 quarter, rolling off would free FCF behind the ~$960M annual dividend.
• Mix-accretive moves into higher-margin electronics/semiconductor materials (SEMICON Taiwan showcase, early September 2026).
• Sell-side dispersion resolving one way or the other: consensus average target $35.67 (8 analysts) versus KeyBanc's $26 and a $45 high.

• Polyethylene oversupply persists and the recovery stalls - the structurally bearish PE view behind KeyBanc's $26 target proves right.
• Dividend coverage: TTM free cash flow of just $436M against roughly $960M of annual cash dividends; a cut would remove the 4.6% yield that currently anchors the valuation.
• Balance-sheet discontinuity: stockholders' equity +60% in one quarter and current liabilities falling from $10.54B to $1.89B leaves a current ratio of 11.07 that is almost certainly an artifact - meaning the score's 78.8 financial-health leg and 63.5 ratio-screener leg are less reliable than they look.
• Volume weakness: a +20% revenue quarter with -1% volumes and -4% P&SP volumes may be price or consolidation that does not repeat.
• Cyclical timing risk: nothing in the data tells you how long the trough lasts - four of six quarters from Q1 2024 to Q2 2025 posted negative free cash flow.
• Income-holder ownership: a 0.42 beta and a large dividend-seeking shareholder base means a payout cut or a downgrade cycle can force selling well beyond what fundamentals justify.

This is a cyclical trough value, not a broken business: 0.84x book, 0.51x sales, ~11.9x forward earnings, a 4.59% yield, a North American feedstock cost advantage, $700M of self-help restructuring, and two consecutive quarters of positive FCF ($621M and $699M) against four negative quarters in the prior six. But the recovery is not self-sustaining yet - volumes are still shrinking, PE oversupply is a real structural overhang, and the Q2 2026 revenue and balance-sheet jumps may be partly inorganic, which is exactly why the deterministic score reads better than the business feels. At $29.03 with a $33 fair value (~14% upside) plus the dividend, the risk/reward is decent for a patient, income-tolerant investor, but I would not call it an urgent buy without either a technical basing signal or PE price confirmation.

I applied a 13.5x P/E - below the company's 26.8x 5-year average (unusable, distorted by near-zero trough earnings) but above the current 11.9x forward - to next-FY consensus EPS of $2.449, giving $33.06, rounded to $33.00. The 13.5x reflects a 0.42-beta, cost-advantaged, 4.6%-yielding commodity chemical producer sitting at a cyclical inflection rather than a mid-cycle peak. Two independent cross-checks converge on the same zone: 1.0x book value is ~$34.4/share (implied by the $20.97B market cap at 0.843x P/B), and a 4.0% required yield on the ~$1.33 annual dividend is ~$33.29.